ADORA2A and Alzheimer disease: Moreover, other clinical trials of neurodegenerative diseases, for instance, AD and PD, exploit the use of BBB-permeable adenosine-related compounds, mainly A2AR agonists and antagonists, alone or in combination with other drugs [96,97].